- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07920601
Effects of C-Tactile-optimal Touch on Alcohol Craving and Relapse-Related Biomarkers in Alcohol Use Disorder
A Pilot Study to Assess the Effects of Mechanic Activation of C-tactile Afferent Nerves on Relapse Predicting Biomarkers and Alcohol Craving in AUD Patients During Early Abstinence, a 4-week Study
The aim of this trial is to investigate the effect of the activation of C-tactile afferents (CT) on relapse predicting biomarkers and subjective alcohol craving in alcohol use disorder (AUD) patients.
To test this in a laboratory environment, we will investigate the acute and chronic effect of mechanic CT activation vs. non-CT-activating control condition during exposure to validated craving-inducing visual stimuli in patients with AUD.We will assess several physiological measures that have been previously shown to indicate craving and predict relapse in patients with substance use disorder. These measures include pupillary reactivity, electroencephalography (EEG), salivary cortisol level and heart rate variability (HRV). These measures, together with the ratings of subjective craving, will be the primary endpoints of the investigation.
Primary objective is to test the hypothesis that CT activation may have therapeutic potential in treatment of AUD. Secondary objective is to investigate the safety and tolerability of mechanic optimal CT activation and its feasibility on modulation of certain biomarkers in AUD population.
40 early abstinent (≥ 2 weeks) female and male individuals of 18 to 60 years of age who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for mild to moderate AUD and who commonly engage in heavy alcohol consumption. However, the participants should precede two weeks of abstinence.
The study will include two experiments (Experiment 1. and Experiment 2.) that are conducted during two separate study visits with maximum seven days in between the visits.
Experiment 1. - Stress-related biomarkers in cue-, stress- and neutral stimuli exposure.
Experiment 1 aims to assess HPA-axis and autonomic nervoussystem reactivity before, during and after exposure to alcohol-, stress-, and neutral visual stimuli while either CT-optimal or non-CT-optimal robotic skin stimulation is provided. The primary biomarkers that will be monitored during the experiment are blood volume pulse (BVP), from which heart rate variability (HRV) will be derived from, and salivary cortisol level. In addition, self-reposted alcohol craving will be measuren with visual analog scale.
Five salivary cortisol samples will be collected at time points -20, -5, 0, +10 and +25. HRV will be derived from BVP and analysed with Kubios HRV Premium software.
All three visual stimuli conditions (neutral, alcohol and stress) will be given during the first study visit.
Experiment 2 - Cue-reactivity task test
In the cue-reactivity task pupillary reactivity, event related potentials (EVP's) of EEG will be measured during alcohol-related and neutral visual stimuli while the CT-optimal or non-CT-optimal skin stimulation is provided. Subjective craving will be self-reported by rating it on a 5-point VAS after each alcohol-related image.
The experiment will take place in an electrically shielded room provided by Aalto Behavioral Laboratory. The pupillary reactivity tracking and the EEG measuring systems will be connected to the PC providing the visual stimuli and the following tasks.
Two types of stimuli - 48 alcohol-related and 48 neutral images - will be presented so that each alcohol related image will be followed by a neutral image. The images will be centered on a white background and the colour, size and brightness of the alcohol and neutral stimuli will be matched. ). After each neutral image, the subject will be presented a question about the predominant colour in the image, which they will answer with the response pad. Once the subject has responded, the next stimulus image will be presented. The trial and the EEG and pupillometry recordings will finnish when the subject has responded to all images. In the end of the laboratory session, the subject will go through a relapse prevention session with an addiction medicine specialist to ensure that the distress caused by the experiments will not trigger a relapse outside of the laboratory.
Relapse prevention sessions
In both experiments the subjects will go through a relapse prevention session with an experienced addiction medicine specialist. The relapse prevention session will take place at the end of each laboratory session, after the exposure to the stimuli. The session consists of short motivational enhancement counselling designed to prevent relapsing.
Follow-up
The experiments will be followed by a two-week period during which the participant will report subjective craving, alcohol consumption and possible adverse events by filling an online diary (Appendix 6). If the participant does not have access to the internet, the diary may be filled manually.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Espoo, Finlandia
- Aalto University, Department of Neuroscience and Biomedical Engineering and Aalto NeuroImaging (ANI) Infrastructure Aalto Behavioral Laboratory
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The subject has blood alcohol cotent of 0.00% at the Visit 1.
- The subject has mild or moderate diagnosis of alcohol use disorder as measured by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
- Males and females aged 18 to 60.
- Able to provide Timeline Follow Back alcohol consumption information for the 28-day period prior to the Visit 1.
- A subject has had ≥6 heavy drinking days in the 4 weeks prior to the online screening.
- The subject has had ≤14 consecutive abstinent days preceding the Visit 1.
- Willingness to provide a saliva sample for cortisol analysis
- Able to read and understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the relapse counselling.
- The subjects must have normal or corrected-to-normal eyesight.
Exclusion Criteria:
- Patients with withdrawal symptoms at the Visit 1, monitored with Clinical Institute Withdrawal Assessment of Alcohol Scale.
- Subjects with diagnosis of any of the following concomitant psychiatric disorders: non-treated, unstable schizophrenia, bipolar disorder, other psychotic disorder during the lifetime of the subject.
5. Subjects with current use of any other addictive substances (excluding nicotine).
6. The subject has been treated with any investigational medicinal product within 30 days.
7. The subject is currently participating or has recently (4 weeks prior to the Visit 1) participated in a treatment program for alcohol use disorders. 8. Dermatological conditions, especially on the targeted anatomical area. E.g., sun burns, cuts, eczema and fungal or other contagious skin diseases.
9. The subject has a clinically significant untreated and unstable illness, for example, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance or chronic atrial fibrillation.
10. Current use of systemic steroids 11. Autism spectrum disorder (ASD). Score 26 or more in The Autism-Spectrum Quotient test.
13. The subject reports treatment, either current or within 28 days prior to the online screening, with any medications having a potential effect on alcohol consumption and related behaviours or mood. These include opiate antagonists (e.g., naltrexone, Vivitrol, Selincro), glutamate antagonists (e.g., acamprosate), anticonvulsants (e.g., topiramate), serotonin reuptake inhibitors (e.g., fluoxetine), serotonin antagonists (e.g., buspirone), other antidepressants (e.g., tricyclic antidepressants or monoamine oxidase inhibitors), dopamine antagonists (e.g., haloperidol), and disulfiram (Antabuse).
14. Current abuse of benzodiazepines. Benzodiazepines are allowed if used chronically.
15. Pregnancy by information given by the patient (non-invasive study). 16. Any other condition or therapy that in the investigator's opinion may pose a risk to the subject, prevent the subject from completing the required study procedures or interfere with the study objectives.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: CT-optimal touch
The active treatment is CT-optimal slow (3 cm/s) stroking tactile stimulation produced with a mechanically moving cosmetic brush |
To eliminate the social aspect present in human touch, we use a robotic device to provide the CT-optimal dynamic touch. Both CT-optimal touch treatment and the non-CT-optimal control treatment are performed with the same custom made robotic device provides dynamic back-and forth strokes with a soft cosmetic brush on the skin of the non-dominant forearm of the participants. The CT-optimal treatment is performed at a velocity of 2.5-3 cm/s and a force of 200-300 mN. The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment. The device is visible to the participants during the experiment.
Altri nomi:
|
|
Comparatore placebo: non-CT-optimal touch
The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment with same robotic device as the Ct-optimal treatment. |
To eliminate the social aspect present in human touch, we use a robotic device to provide the CT-optimal dynamic touch. Both CT-optimal touch treatment and the non-CT-optimal control treatment are performed with the same custom made robotic device provides dynamic back-and forth strokes with a soft cosmetic brush on the skin of the non-dominant forearm of the participants. The CT-optimal treatment is performed at a velocity of 2.5-3 cm/s and a force of 200-300 mN. The non-CT-optimal control treatment is performed with velocity of 0.1-0.2 cm/s and a force similar to the CT-optimal treatment. The device is visible to the participants during the experiment.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Heart rate variability (HRV) reactivity as a biomarker of stress and a predictor of susceptibility to relapse
Lasso di tempo: Measurement taken during each participant's first study visit for approximately 32 minutes.
|
To assess autonomic functioning, Standard deviation of normal-to-normal intervals (SDNN) HRV (ms) is derived from blood volume pulse (BVP) measured with Empatica E4 wrist band device throughout Experiment 1. excluding a 15-minute relaxation at the end of the experimental session. |
Measurement taken during each participant's first study visit for approximately 32 minutes.
|
|
Self-reported Alcohol craving
Lasso di tempo: The first and second study visits. Maximum 7 days in between the visits.
|
In the experiment performed during the first study visit a visual analog scale to assess self-reported subjective craving is shown before and after each cue exposure. The guestion "If alcohol was available to me right now..." is shown with a ten-point scale in which 1 = I would not want to drink it at all, 10 = I would not be able to resist drinking even if I tried. In the experiment at the second study visit a five-point visual analog scale for rating the alcohol craving is shown after each alcohol-related image in the cue reactivity task. In this on the queston is "How willing are you to drink the drink in the previous image…" 1 = I would not want to drink it at all, 5 = I would not be able to resist drinking even if I tried. |
The first and second study visits. Maximum 7 days in between the visits.
|
|
Salivary cortisol as a biomarker of stress and a predictor of susceptibility to relapse
Lasso di tempo: First study visit. The time points of the saliva collection were the baseline, after the first 10 minutes of the treatment, after the visual stimuli, at the end of the treatment and after the 15-minute relaxation period.
|
To assess the salivary cortisol levels (ng/ml), saliva samples are collected 5 times during the Experiment 1. (total 15 samples per participant). The saliva is collected by placing a synthetic swab between the tongue and the cheek of the participants for minimum 2 min after which it was placed in a plastic tube and stored in -20 °C until the analysis. |
First study visit. The time points of the saliva collection were the baseline, after the first 10 minutes of the treatment, after the visual stimuli, at the end of the treatment and after the 15-minute relaxation period.
|
|
Pupillary reactivity as a predictor of susceptibility to relapse
Lasso di tempo: Second study visit (maximum 7 seven days after ensrollment). Recorded during a cue reactivity task test for approximately 5 minutes.
|
Pupillary reactivity measurements are conducted in the Aalto Behavioral Laboratory (ABL) using an EyeLink 1000 Plus eye-tracking system during the Experiment 2. Pupil size (mm) is recorded continuously throughout the cue-reactivity task at a sampling frequency of 500 Hz. Pupil size is recorded monocularly from the participant's dominant eye, as determined prior to the session. |
Second study visit (maximum 7 seven days after ensrollment). Recorded during a cue reactivity task test for approximately 5 minutes.
|
|
Event related potentials (ERP's) of electroencephalography (EEG) as a biomarker for predicting a vulnerability to relapses
Lasso di tempo: Second study visit (maximum 7 seven days after ensrollment. EEG will be recorded though out the cue reactivity task test for approximately 5 minute.
|
ERPs (microVolts) of EEG will be recorded using an BrainAmp amplifier and an ActiCap 32-channel electrode set during the cue reactivity task test (Experiment 2.) Focus will be on P3 amplitudes. Patients with AUD, as well as other substance use disorders, have larger P3 amplitudes elicited by substance-related than neutral stimuli which indicates that P3 amplitudes reflect the neural correlates of substance craving . In addition, the AUD patients with reduced P3 amplitudes to alcohol cues are less likely to relapse than those with larger P3 amplitudes. |
Second study visit (maximum 7 seven days after ensrollment. EEG will be recorded though out the cue reactivity task test for approximately 5 minute.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of patients experiensing adverse reactions (Safety and Tolerability)
Lasso di tempo: 3 weeks from the enrollment (First and second study visits and a two-week follow-up)
|
Number of patients experiensing adverse reactions during the experimets and follow-up and numer of reported reactions |
3 weeks from the enrollment (First and second study visits and a two-week follow-up)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Hannu Alho, Professor Emeritus, PhD, MD, University of Helsinki
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- AY-NBE-HT-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data cannot be shared due to the GDPR regulations.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .